Can MI Patients Have Negative Troponin Due to Anti-Troponin Antibodies?
Yes, patients with myocardial infarction can have falsely negative troponin results due to anti-troponin antibodies, though this is rare and current assays have largely overcome this deficiency. This represents a critical diagnostic pitfall that can delay life-saving treatment in acute coronary syndromes.
The Evidence on Anti-Troponin Antibody Interference
The European Society of Cardiology guidelines explicitly acknowledge that troponin I can produce false-negative results related to interaction with heterophilic antibodies 1. While current assays have largely overcome these deficiencies, the guidelines caution that "infrequent false-positive results may still occur" - and by extension, false-negative results remain possible 1.
More recent research confirms this concern is real:
- Anti-cardiac troponin autoantibodies (cTnAAbs) can cause false-negative troponin measurements by interfering with immunoassay detection 2, 3
- These antibodies are specific to conformational epitopes formed when cardiac troponin I and T combine in the ternary troponin complex 3
- The interference is assay-dependent: one study found that approximately 5-10% of patients at early stages of AMI could have underestimated troponin concentrations when measured by cTnAAb-sensitive immunoassays 3
- Recent 2025 data demonstrates that 10% of MI patients were cTnAAb-positive, and these antibodies can prolong troponin elimination and reduce clearance 4
The 2011 ACC/AHA guidelines specifically note: "Rare patients may have blocking antibodies to part of the troponin molecule, which would result in false-negative results" 5.
Clinical Implications and Risk Mitigation
This creates a dangerous scenario where a patient with genuine MI could be inappropriately discharged or denied urgent revascularization based on falsely reassuring troponin results.
Practical Approach When Suspecting False-Negative Troponin:
Never rely on a single troponin measurement - Guidelines mandate troponin measurement at presentation AND 3-6 hours later, with additional measurements beyond 6 hours if initial values are normal but clinical suspicion remains high 1, 6, 7
Clinical context trumps laboratory values - If a patient presents with:
- Typical ischemic chest pain
- ECG changes suggestive of ischemia (ST depression >1mm, T-wave inversion)
- High pre-test probability for ACS
Proceed with treatment for ACS regardless of initial negative troponin 1
Use alternative biomarkers when available:
Consider alternative troponin assays: Different commercial assays show variable susceptibility to cTnAAb interference 4, 9. If results conflict with clinical presentation, request measurement with a different assay platform or point-of-care testing 10
Remember timing: 10-15% of patients may not show troponin elevation on initial hospital arrival 1. The cytosolic pool releases troponin 3-4 hours after MI onset 1
Common Pitfalls to Avoid
Do not discharge a patient with ongoing chest pain and ECG changes based solely on negative troponin - This accounts for the 5% of patients with normal ECGs who were inappropriately discharged and later found to have MI 1
Beware of the "completely normal ECG" - This does not exclude ACS, particularly with left circumflex or right coronary occlusions that can be electrically silent 7
Don't confuse false-negatives with timing issues - Most "negative" troponins in early MI are simply too early, not antibody interference. Serial measurements over 6-12 hours are mandatory 1, 6
The Bottom Line
While anti-troponin antibodies causing false-negative results are uncommon (affecting roughly 5-10% of patients), the mortality implications of missing an MI are catastrophic. The guideline-mandated approach of serial troponin measurements combined with clinical assessment and ECG monitoring provides the safety net to catch these cases. When troponin results conflict with a compelling clinical picture of ACS, treat the patient, not the laboratory value, and pursue alternative diagnostic confirmation through repeat testing with different assays or additional cardiac biomarkers 1, 5, 3.